BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Pancreatic cancer AND TSC2, FLJ43106, 7249, ENSG00000103197, LAM, tuberin, TSC4 AND Treatment
11 results:

  • 1. SNHG15 promotes gallbladder cancer progression by enhancing the autophagy of tumor cell under nutrition stress.
    Min H; Yang L; Xu X; Geng Y; Liu F; Liu Y
    Cell Cycle; 2023 Oct; 22(19):2130-2141. PubMed ID: 37937948
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Tuberous sclerosis complex mutations in patients with pancreatic neuroendocrine tumors. Observations on phenotypic and treatment-related associations.
    Navale P; Chatterjee D; Itani M; Trikalinos NA
    Virchows Arch; 2023 Aug; 483(2):167-175. PubMed ID: 37354253
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Simultaneous activation of Kras-Akt and Notch pathways induces extrahepatic biliary cancer via the mTORC1 pathway.
    Namikawa M; Fukuda A; Mizukoshi K; Iwane K; Kawai M; Yamakawa G; Omatsu M; Sono M; Masuda T; Araki O; Nagao M; Yoshikawa T; Ogawa S; Hiramatsu Y; Muta Y; Tsuda M; Maruno T; Nakanishi Y; Tsuruyama T; Taura K; Hatano E; Seno H
    J Pathol; 2023 Aug; 260(4):478-492. PubMed ID: 37310065
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Molecular and Functional Heterogeneity of Primary pancreatic Neuroendocrine Tumors and Metastases.
    Guo Y; Tian C; Cheng Z; Chen R; Li Y; Su F; Shi Y; Tan H
    Neuroendocrinology; 2023; 113(9):943-956. PubMed ID: 37232011
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Molecular profiling and target actionability for precision medicine in neuroendocrine neoplasms: real-world data.
    Boilève A; Faron M; Fodil-Cherif S; Bayle A; Lamartina L; Planchard D; Tselikas L; Kanaan C; Scoazec JY; Ducreux M; Italiano A; Baudin E; Hadoux J
    Eur J Cancer; 2023 Jun; 186():122-132. PubMed ID: 37062210
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Mechanistic Target of Rapamycin (mTOR) Inhibitors.
    Wang D; Eisen HJ
    Handb Exp Pharmacol; 2022; 272():53-72. PubMed ID: 35091825
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Successful Immunotherapy for pancreatic cancer in a Patient With tsc2 and SMAD4 Mutations: A Case Report.
    Ye Y; Zheng S
    Front Immunol; 2021; 12():785400. PubMed ID: 34880877
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Death-associated protein kinase 1 promotes growth of p53-mutant cancers.
    Zhao J; Zhao D; Poage GM; Mazumdar A; Zhang Y; Hill JL; Hartman ZC; Savage MI; Mills GB; Brown PH
    J Clin Invest; 2015 Jul; 125(7):2707-20. PubMed ID: 26075823
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. pancreatic neuroendocrine tumor in a child with a tuberous sclerosis complex 2 (tsc2) mutation.
    Bombardieri R; Moavero R; Roberto D; Cerminara C; Curatolo P
    Endocr Pract; 2013; 19(5):e124-8. PubMed ID: 23757617
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. New insights into the role of the tuberous sclerosis genes in leukemia.
    Rosner M; Fuchs C; Siegel N; Valli A; Hengstschläger M
    Leuk Res; 2009 Jul; 33(7):883-5. PubMed ID: 19286253
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Molecular genetics of gastroenteropancreatic neuroendocrine tumors.
    Starker LF; Carling T
    Curr Opin Oncol; 2009 Jan; 21(1):29-33. PubMed ID: 19125015
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.